345 related articles for article (PubMed ID: 16142319)
1. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
Martín P; Santón A; García-Cosío M; Bellas C
Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
[TBL] [Abstract][Full Text] [Related]
2. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
Matozaki S; Nakagawa T; Nakao Y; Fujita T
Kobe J Med Sci; 1991 Feb; 37(1):35-45. PubMed ID: 1921261
[TBL] [Abstract][Full Text] [Related]
3. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
4. Oncogenes in multiple myeloma: point mutation of N-ras.
Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
[TBL] [Abstract][Full Text] [Related]
5. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
6. A high frequency of N-RAS oncogene mutations in multiple myeloma.
Tanaka K; Takechi M; Asaoku H; Dohy H; Kamada N
Int J Hematol; 1992 Oct; 56(2):119-27. PubMed ID: 1421173
[TBL] [Abstract][Full Text] [Related]
7. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
Bezieau S; Devilder MC; Avet-Loiseau H; Mellerin MP; Puthier D; Pennarun E; Rapp MJ; Harousseau JL; Moisan JP; Bataille R
Hum Mutat; 2001 Sep; 18(3):212-24. PubMed ID: 11524732
[TBL] [Abstract][Full Text] [Related]
8. The significance of soluble CD138 in diagnosis of monoclonal gammopathies.
Maisnar V; Tousková M; Tichý M; Krejsek J; Chrobák L; Voglová J; Malý J
Neoplasma; 2006; 53(1):26-9. PubMed ID: 16416009
[TBL] [Abstract][Full Text] [Related]
9. [Immunoglobulin heavy chain gene rearrangements in the monoclonal gammopathies].
Bosaleh A; Denninghoff V; Garcia A; Rescia C; Avagnina A; Elsner B
Medicina (B Aires); 2005; 65(3):219-25. PubMed ID: 16042132
[TBL] [Abstract][Full Text] [Related]
10. Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia.
Schaar CG; Vermeer HJ; Wijermans PW; Huisman W; le Cessie S; Kluin-Nelemans HC
Haematologica; 2005 Oct; 90(10):1437-8. PubMed ID: 16219583
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
Corradini P; Inghirami G; Astolfi M; Ladetto M; Voena C; Ballerini P; Gu W; Nilsson K; Knowles DM; Boccadoro M
Leukemia; 1994 May; 8(5):758-67. PubMed ID: 8182933
[TBL] [Abstract][Full Text] [Related]
12. [Monoclonal gammopathies of undetermined significance].
Krizalkovicová V; Maisnar V; Pour L; Radocha J; Hájek R
Klin Onkol; 2008; 21(4):160-4. PubMed ID: 19102222
[TBL] [Abstract][Full Text] [Related]
13. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance.
Zojer N; Schuster-Kolbe J; Assmann I; Ackermann J; Strasser K; Hübl W; Drach J; Ludwig H
Br J Haematol; 2002 Jun; 117(4):852-9. PubMed ID: 12060120
[TBL] [Abstract][Full Text] [Related]
15. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
[TBL] [Abstract][Full Text] [Related]
16. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
17. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies.
Seidl S; Ackermann J; Kaufmann H; Keck A; Nösslinger T; Zielinski CC; Drach J; Zöchbauer-Müller S
Cancer; 2004 Jun; 100(12):2598-606. PubMed ID: 15197802
[TBL] [Abstract][Full Text] [Related]
18. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.
Corradini P; Ladetto M; Voena C; Palumbo A; Inghirami G; Knowles DM; Boccadoro M; Pileri A
Blood; 1993 May; 81(10):2708-13. PubMed ID: 8490179
[TBL] [Abstract][Full Text] [Related]
19. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
International Myeloma Working Group
Br J Haematol; 2003 Jun; 121(5):749-57. PubMed ID: 12780789
[TBL] [Abstract][Full Text] [Related]
20. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
